The Biospecimen Core (Core 2) is the cornerstone of all Yale SPORE in Skin Cancer (YSPORE) activities. It addresses the broad melanoma patient specimen needs of all the projects that are not met by current shared facilities at Yale. In addition to collecting, storing and distributing a wide range of specimens and reagents, the core performs quality assurance testing and a wide range of molecular analyses of specimens. More specifically, the core: a) collects a large repertoire of specimens for translational and preclinical studies in melanoma, including melanocytic lesions, melanoma tumors and cells, normal skin, serum, and circulating lymphocytes; b) ensures high quality control, proper long-term storage, detailed annotation, and timely distribution of specimens to YSPORE investigators; c) establishes and maintains a central database of essential pathological, clinical, epidemiological, and follow-up information and basic research data generated by the YSPORE projects that is integrated with the Biostatistics and Bioinformatics Core; d) provides special services such as the analysis of specimens from clinical trials, mutations, chromatin modification, and collection of TIL (tumor infiltrating lymphocytes); e) maintains and distributes validated reagents (antibodies, oligonucleotides for PCR, DNA, RNA, plasmids, cell extracts) needed for molecular analyses of tumors by different YSPORE investigators; f) establishes links with shared facilities at Yale and similar resources in other institutions, including other SPOREs; g) distributes samples to collaborating investigators outside of Yale; and h) provides specimens for larger NCI objectives, such as melanoma specimens, peripheral blood lymphocytes, and annotated clinical data for The Cancer Genome Atlas (TCGA). The core interacts extensively with investigators in each project, the Bioinformatics and Biostatistics Core, the Clinical Trial Office, and Yale Cancer Center shared resource cores such as Yale Pathology Tissue Services and Yale Center for Genome Analysis. The services of the Biospecimen Resource Core enhance the efficient operation of the translational studies by YSPORE investigators in a cost-effective manner, and expedite the application of discoveries from the bench to clinical practice, and clinical results to basic research.

Public Health Relevance

BIOSPECIMEN CORE: PROJECT NARRATIVE Biospecimen Core (Core 2), provides a variety of clinically annotated samples (tumor, normal skin, plasma, peripheral blood lymphocytes, tumor infiltrating lymphocytes, serum, short term cultures, DNA and RNA) to SPORE investigators and other collaborators at Yale and outside of Yale. Integration with Core 3 for storage of data is key to maximizing utilization of specimens and distribution of samples is governed by a Tissue Committee. The Core is central to the all the activities of YSPORE and well integrated with pathology and clinical services at Yale Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA121974-11A1
Application #
9567744
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
11
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
Ferrucci, Leah M; Cartmel, Brenda; Clare, Rachel A et al. (2018) Cross-sectional assessment of ultraviolet radiation-related behaviors among young people after a diagnosis of melanoma or basal cell carcinoma. J Am Acad Dermatol 79:149-152
Arbesman, Joshua; Ravichandran, Sairekha; Funchain, Pauline et al. (2018) Melanoma cases demonstrate increased carrier frequency of phenylketonuria/hyperphenylalanemia mutations. Pigment Cell Melanoma Res 31:529-533
Perry, Curtis J; Muñoz-Rojas, Andrés R; Meeth, Katrina M et al. (2018) Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. J Exp Med 215:877-893
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Sulkowski, Parker L; Scanlon, Susan E; Oeck, Sebastian et al. (2018) PTEN Regulates Nonhomologous End Joining By Epigenetic Induction of NHEJ1/XLF. Mol Cancer Res 16:1241-1254
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Krauthammer, Michael (2018) Unraveling the etiology of primary malignant melanoma of the esophagus. J Thorac Dis 10:S1074-S1075
Das, Rituparna; Bar, Noffar; Ferreira, Michelle et al. (2018) Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest 128:715-720
Miller, Chad J; Muftuoglu, Yagmur; Turk, Benjamin E (2017) A high throughput assay to identify substrate-selective inhibitors of the ERK protein kinases. Biochem Pharmacol 142:39-45
Kluger, Harriet M; Zito, Christopher R; Turcu, Gabriela et al. (2017) PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clin Cancer Res 23:4270-4279

Showing the most recent 10 out of 172 publications